May 12th 2024
Training at a major academic center offers firsthand exposure to groundbreaking 177Lu-PSMA-617 treatment for advanced prostate cancer.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
KEYNOTE-921 Trial of Pembrolizumab and Chemo Fails to Improve Survival in mCRPC
August 10th 2022The phase 3 KEYNOTE-921 trial did not meet its coprimary end points of overall survival and radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer.
Read More
Sabizabulin Deemed Safe in Metastatic Castration-Resistant Prostate Cancer
July 14th 2022In the interview, Mark Markowski, MD, discussed how the findings from the phase 1/2 trial of sabizabulin in patients with metastatic castration-resistant prostate cancer this may influence future research with the oral agent.
Read More